Serum Levels of miR-155, miR-326, and miR-133b as Early Diagnostic Biomarkers for the Detection of Human Acute Heart Allograft Rejection in Comparison with Serum Cardiac Troponin T

Authors

  • Aghil Esmaeili-bandboni Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran Heart Center, Tehran, Iran
  • Jamshid Bagheri Department Cardiovascular Surgery, Tehran Heart Center, Tehran, Iran
  • Ali Reza Bakhshandeh Cardiovascular Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  • Javad Mohammadnejad Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran
  • Esmaeil Sadroddiny Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran Heart Center, Tehran, Iran

DOI:

https://doi.org/10.1532/hsf.1887

Keywords:

Heart transplantations, Rejection, Graft, miRNAs, Troponin-T

Abstract

Background: Acute heart allograft rejection occurs as a result of antibody-mediated rejection that presents during the first month after transplantation. Finding a non-invasive biomarker is essential for diagnosis of heart allograft rejection. In this research, we intended to compare expression levels of several microRNAs across cardiac troponin T levels between rejected patients (who died before one month following transplantation), non-rejected patients (who survived for at least one month after transplantation), and non-transplanted patients (CABG surgery patients).

Methods: Serum levels of miR-155, miR-326, and miR-133b were evaluated by the q-RT-PCR method. Furthermore, cardiac troponin T levels were measured by a highly sensitive electrochemiluminescence assay. Finally, the data were analyzed by independent sample t-test using SPSS 21® computer software. 

Results: It was observed that miR-326 and miR-155 expression levels increased after 24h and 72h of surgery in rejected patients compared with the two other groups, but these increases were not statistically significant. Moreover, the decrease in miR-133b expression level was non-significant after transplantation in the rejected group compared with the non-rejected group. However, cTnT levels in rejected patients increased significantly compared with the other groups (P < .05). After ROC curve analysis, the cTnT marker with the most area under the curve (AUC = 1.00, 95% confidence interval, 1.00 to 1.00; P = .006), had the best discriminatory power, and among microRNAs, miR-326 had the largest area under curve (AUC = 0.81), and consequently the highest discriminatory power.

Conclusions: We demonstrated that troponin T can be a more efficient biomarker than miRNAs for early prediction of human death caused by acute heart rejection, and the ROC curves analysis verified this finding.

References

Al-Mohaissen M A and Virani S A. 2014. Allosensitization in heart transplantation: an overview. Can J Cardiol 30:161-172.

Alexis J D, Lao C D, Selter J G, et al. 1998. Cardiac troponin T: a noninvasive marker for heart transplant rejection? J Heart Lung Transplant 17:395-398.

Billingham M, Cary N, Hammond M, et al. 1990. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9:587-593.

Busk P K. 2014. A tool for design of primers for microRNA-specific quantitative RT-qPCR. BMC Bioinformatics 15:29.

Carrier M, Russell D, Wild J, et al. 1986. Prolactin as a marker of rejection in human heart transplantation. J Heart Transplant 6:290-292.

Dewi I S, Torngren K, Gidlöf O, et al. 2013. Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. J Heart Lung Transplant 32:463-466.

Djamali A, Kaufman D, Ellis T, et al. 2014. Diagnosis and management of antibody-mediated rejection: Current status and novel approaches. Am J Transplantation 14:255-271.

Giannitsis E, Kurz K, Hallermayer K, et al. 2010. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 56:254-261.

Gradek W Q, D’Amico C, Smith A L, et al. 2001. Routine surveillance endomyocardial biopsy continues to detect significant rejection late after heart transplantation. J Heart Lung Transplant 20:497-502.

Haas J D, Nistala K, Petermann F, et al. 2011. Expression of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-17 production in αβ and γδ T cells. PLoS One 6:e20171.

Hammer S, Meisner F, Dirschedl P, et al. 1998. Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transplant Immunol 6:235-241.

Hanczar B, Hua J, Sima C, et al. 2010. Small-sample precision of ROC-related estimates. Bioinformatics 26:822-830.

Krol J, Loedige I and Filipowicz W. 2010. The widespread regulation of microRNA biogenesis, function and decay. Nature Reviews Genetics 11:597-610.

Kwekel J C, Vijay V, Desai V G, et al. 2015. Age and sex differences in kidney microRNA expression during the life span of F344 rats. Biol Sex Differ 6:1.

Li Y-Q, Zhang M-F, Wen H-Y, et al. 2013. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics 68:75-80.

Ling H, Fabbri M and Calin G A. 2013. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews Drug discovery 12:847-865.

Michaels P J, Espejo M L, Kobashigawa J, et al. 2003. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22:58-69.

Muñoz-Esparza C, Garrido I P, Blanco R, et al. 2011. Usefulness of high sensitivity troponin T assay in detecting acute allograft rejection after heart transplantation. Revista Española de Cardiología (English Edition) 64:1109-1113.

Patel P C, Hill D A, Ayers C R, et al. 2014. High-Sensitivity Cardiac Troponin I Assay to Screen for Acute Rejection in Patients With Heart Transplant CLINICAL PERSPECTIVE. Circ Heart Fail 7:463-469.

Patron J P, Fendler A, Bild M, et al. 2012. MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. PLoS One 7:e35345.

Pfaffl M W. 2001. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res 29:e45-e45.

Pfaffl M W. Quantification strategies in real-time PCR. In: Bustin, Stephen A. 2004. A-Z of quantitative PCR. La Jolla, CA: International University Line. 87:112.

Racusen L C, Colvin R B, Solez K, et al. 2003. Antibody-Mediated Rejection Criteria–an Addition to the Banff′ 97 Classification of Renal Allograft Rejection. Am J Transplantation 3:708-714.

Reed E F, Demetris A J, Hammond E, et al. 2006. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 25:153-159.

Reichlin T, Hochholzer W, Bassetti S, et al. 2009. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. New Engl J Med 361:858-867.

Rodriguez E, Skojec D V, Tan C D, et al. 2005. Antibody-Mediated Rejection in Human Cardiac Allografts: Evaluation of Immunoglobulins and Complement Activation Products C4d and C3d as Markers. Am J Transplantation 5:2778-2785.

Shi R, Sun Y-H, Zhang X-H, et al. 2012. Poly (T) Adaptor RT-PCR. Next-Generation MicroRNA Expression Profiling Technology: Methods and Protocols 53-66.

Siaplaouras J, Thul J, Kramer U, et al. 2003. Cardiac troponin I: a marker of acute heart rejection in infant and child heart recipients? Pediatr Transplant 7:43-45.

Simon L M, Edelstein L C, Nagalla S, et al. 2014. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 123:e37-e45.

Taylor D O, Yowell R L, Kfoury A G, et al. 2000. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 19:518-521.

Trotta R, Chen L, Ciarlariello D, et al. 2012. miR-155 regulates IFN-γ production in natural killer cells. Blood 119:3478-3485.

Van Huyen J-P D, Tible M, Gay A, et al. 2014. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur Heart J 35:194-3202.

Wang E, Nie Y, Zhao Q, et al. 2013a. Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. J Cardiothorac Surg 8:1.

Wang E, Nie Y, Zhao Q, et al. 2013b. Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. Journal of cardiothoracic surgery 8:165.

Wei L, Wang M, Qu X, et al. 2012. Differential expression of microRNAs during allograft rejection. Am J Transplantation 12:1113-1123.

Wilflingseder J, Regele H, Perco P, et al. 2013. miRNA profiling discriminates types of rejection and injury in human renal allografts. Transplantation 95:835.

Yu S, Huang H, Deng G, et al. 2015. miR-326 targets antiapoptotic Bcl-xL and mediates apoptosis in human platelets. PLoS One 10:e0122784.

Zimmermann R, Baki S, Dengler T, et al. 1993. Troponin T release after heart transplantation. Br Heart J 69:395-398.

Published

2018-03-12

How to Cite

Esmaeili-bandboni, A., Bagheri, J., Bakhshandeh, A. R., Mohammadnejad, J., & Sadroddiny, E. (2018). Serum Levels of miR-155, miR-326, and miR-133b as Early Diagnostic Biomarkers for the Detection of Human Acute Heart Allograft Rejection in Comparison with Serum Cardiac Troponin T. The Heart Surgery Forum, 21(2), E101-E107. https://doi.org/10.1532/hsf.1887

Issue

Section

Article